Audit and its impact in the management of advanced prostatic cancer.
From a prospective database of 614 consecutive men with newly diagnosed prostatic cancer an audit of outcome was studied in 169 men who presented with bone metastases and subsequently received hormonal manipulation in the form of monotherapy. The cohort was divided into 2 groups according to serum alkaline and acid phosphatase enzyme levels. Men with normal alkaline phosphatase levels (41.5%) had a better prognosis (median survival 38 months) than those with elevated levels at presentation (58.5%) (median survival 19 months). This difference was highly significant. A similar stratification on prostatic acid phosphatase levels did not yield any prognostic significance. With regard to cause-specific survival, serum alkaline phosphatase was an even more powerful prognosticator, with a median survival of 45 and 21 months for patients with normal and elevated levels respectively. Thus monotherapy is recommended for metastatic prostate cancer patients with normal serum alkaline phosphatase, but for those with elevated alkaline phosphatase the alternative avenues of treatment must be explored.
Rana
A
A
University Department of Surgery/Urology, Western General Hospital, Edinburgh.
Chisholm
G D
GD
Christodoulou
S
S
McIntyre
M
M
Elton
R A
RA
D000135:Acid Phosphatase / Q000097:blood; D000368:Aged; D000469:Alkaline Phosphatase / Q000097:blood; D014408:Biomarkers, Tumor / Q000097:blood; D001859:Bone Neoplasms / Q000556:secondary; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D009919:Orchiectomy; D011379:Prognosis; D011446:Prospective Studies; D011471:Prostatic Neoplasms / Q000097:blood / Q000201:enzymology / Q000401:mortality / Q000601:surgery*; D016896:Treatment Outcome
D014408:Biomarkers, Tumor; D000469:Alkaline Phosphatase; D000135:Acid Phosphatase